WallStSmart

Clover Health Investments Corp (CLOV)vsElevance Health Inc (ELV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Elevance Health Inc generates 8999% more annual revenue ($201.11B vs $2.21B). ELV leads profitability with a 2.5% profit margin vs -2.6%. ELV earns a higher WallStSmart Score of 55/100 (C-).

CLOV

Avoid

34

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 6.7Quality: 3.8
Piotroski: 2/9Altman Z: -1.87

ELV

Buy

55

out of 100

Grade: C-

Growth: 4.0Profit: 5.0Value: 6.7Quality: 6.5
Piotroski: 4/9Altman Z: 2.66
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLOVUndervalued (+69.1%)

Margin of Safety

+69.1%

Fair Value

$6.63

Current Price

$4.23

$2.40 discount

UndervaluedFair: $6.63Overvalued
ELVUndervalued (+7.5%)

Margin of Safety

+7.5%

Fair Value

$416.99

Current Price

$375.98

$41.01 discount

UndervaluedFair: $416.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLOV1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
62.0%10/10

Revenue surging 62.0% year-over-year

ELV4 strengths · Avg: 8.3/10
Market CapQuality
$85.33B9/10

Large-cap with strong market position

P/E RatioValuation
16.9x8/10

Attractively priced relative to earnings

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.63B8/10

Generating 1.6B in free cash flow

Areas to Watch

CLOV4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.6%3/10

Operating margin of 3.6%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-16.8%2/10

ROE of -16.8% — below average capital efficiency

ELV4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Profit MarginProfitability
2.5%3/10

2.5% margin — thin

Operating MarginProfitability
4.6%3/10

Operating margin of 4.6%

EPS GrowthGrowth
-13.1%2/10

Earnings declined 13.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : CLOV

The strongest argument for CLOV centers on Revenue Growth. Revenue growth of 62.0% demonstrates continued momentum.

Bull Case : ELV

The strongest argument for ELV centers on Market Cap, P/E Ratio, Price/Book. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bear Case : CLOV

The primary concerns for CLOV are EPS Growth, Operating Margin, Piotroski F-Score.

Bear Case : ELV

The primary concerns for ELV are Revenue Growth, Profit Margin, Operating Margin. Thin 2.5% margins leave little buffer for downturns.

Key Dynamics to Monitor

CLOV profiles as a hypergrowth stock while ELV is a value play — different risk/reward profiles.

CLOV carries more volatility with a beta of 2.42 — expect wider price swings.

CLOV is growing revenue faster at 62.0% — sustainability is the question.

ELV generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

ELV scores higher overall (55/100 vs 34/100). CLOV offers better value entry with a 69.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Clover Health Investments Corp

HEALTHCARE · HEALTHCARE PLANS · USA

Clover Health Investments, Corp. The company is headquartered in Franklin, Tennessee.

Visit Website →

Elevance Health Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Elevance Health Inc. is a health benefits company. The company is headquartered in Indianapolis, Indiana.

Want to dig deeper into these stocks?